This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
Blood Cancer Journal Open Access 14 August 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Murphy S . Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999; 36 (1 Suppl 2): 9–13.
Tefferi A . The rise and fall of red cell mass measurement in polycythemia vera. Curr Hematol Rep 2005; 4: 213–217.
Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ . Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013; 122: 1881–1886.
McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130: 174–195.
Barbui T, Thiele J, Carobbio A, Guglielmelli P, Rambaldi A, Vannucchi A et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol 2014; 89: 588–590.
Thiele J, Kvasnicka HM . Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol 2005; 20: 317–328.
Tefferi A, Thiele J, Vannucchi AM, Barbui T . An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014; e-pub ahead of print 20 January 2014; doi:10.1038/leu.2014.35.
Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179–3184.
Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H et al. (eds) WHO Classification of Tumours of Haematopoietic and Lympoid Tissues. IARC Press: Lyon, France, 2008.
Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.
Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544–1551.
Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014; 123: 1552–1555.
Tefferi A, Wassie EA, Lasho TL, Finke C, Belachew AA, Ketterling RP et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014; e-pub ahead of print 5 May 2014; doi:1038/leu.2014.148.
Thiele J, Kvasnicka HM, Diehl V . Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005; 113: 213–219.
Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 2012; 25: 1193–1202.
Acknowledgements
TB and AMV were supported by a grant from Associazione Italiana per la Ricerca sul Cancro (AIRC, Milano) ‘Special Program Molecular Clinical Oncology 5 × 1000’ to AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Barbui, T., Thiele, J., Kvasnicka, H. et al. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. Leukemia 28, 2092–2094 (2014). https://doi.org/10.1038/leu.2014.175
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.175
This article is cited by
-
The WHO diagnostic criteria for polycythemia vera—role of red cell mass versus hemoglobin/hematocrit level and morphology
Annals of Hematology (2018)
-
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
Blood Cancer Journal (2015)